Gene expression profiling of breast cancer: a new tumor marker.

In ideal clinical oncology practice, one would like to have a single platform assay that can provide both prognostic (estimates of risk for failure after surgery alone) and predictive (estimate of benefit from specific therapy) information. Despite years of research, only estrogen receptors (ER), progesterone receptors, and HER-2 have been widely accepted for routine use in breast cancer, serving as predictive factors for endocrine and trastuzumab therapy, respectively. Until recently, new markers have been tested one, or at most two, at a time, a process that results in inefficient tissue usage, long delays in analysis, and, if positive, implementation.

[1]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[5]  T. Karn,et al.  Molecular classification of breast cancer patients by gene expression profiling * , 2001, The Journal of pathology.

[6]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[7]  F. Muggia,et al.  Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.

[8]  G. Sauter,et al.  Predictive molecular pathology. , 2002, The New England journal of medicine.

[9]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Cady.  New era in breast cancer. Impact of screening on disease presentation. , 1997, Surgical oncology clinics of North America.

[11]  Norman Wolmark,et al.  Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 , 2003 .

[12]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[13]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[15]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[16]  Young-Duck Kim,et al.  E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide , 2003, Breast Cancer Research and Treatment.

[17]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[18]  J. Bryant,et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.

[19]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[20]  M. Ellis,et al.  Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Korah,et al.  Expression of FGF-2 alters focal adhesion dynamics in migration-restricted , 2004, Breast Cancer Research and Treatment.

[22]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Daniel F. Hayes,et al.  Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.

[26]  Richard L Schilsky,et al.  Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.